Biotech Dives After European Regulators Reject Eye Drug — Again
European regulators rejected Apellis Pharmaceuticals' (APLS) embattled eye drug, Syfovre. Apellis stock tumbled to a month-low. ↑ X NOW PLAYING How To Sell Stocks: Long-Term Trend Lines The Committee for Medicinal Products for Human Use, an arm of the …